Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Urología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Desconocido
ClinicalTrials.gov
Impact Analysis of Email Reminders on No-Show Rates in Scheduled Ambulatory Appointments in the Urology Department of Hospital Italiano de Buenos Aires
OBSERVATIONAL
Inicio: 1 de ene de 2022
ID: NCT06114602
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.
INTERVENTIONAL
Inicio: 28 de jul de 2025
ID: NCT06858319
Desconocido
ClinicalTrials.gov
A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
EXPANDED_ACCESS
Inicio: 1 de jul de 2005
ID: NCT00130897
Completado
ClinicalTrials.gov
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
OBSERVATIONAL
Inicio: 1 de jul de 2006
ID: NCT00895674
Completado
Fase 2
ClinicalTrials.gov
Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria
INTERVENTIONAL
Inicio: 1 de feb de 2006
ID: NCT00296374
Completado
ClinicalTrials.gov
PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib
OBSERVATIONAL
Inicio: 19 de jul de 2012
ID: NCT01649778
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer
INTERVENTIONAL
Inicio: 23 de mar de 2023
ID: NCT05714202
Aún no recluta
Fase 2
ClinicalTrials.gov
A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy
INTERVENTIONAL
Inicio: 1 de abr de 2026
ID: NCT06972615
Completado
Fase 2
ClinicalTrials.gov
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
INTERVENTIONAL
Inicio: 28 de feb de 2020
ID: NCT04172675
Terminado
ClinicalTrials.gov
TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
INTERVENTIONAL
Inicio: 13 de feb de 2019
ID: NCT04436120
Aún no recluta
ClinicalTrials.gov
Development and Validation of an Obstetric Organ Dysfunction Score to Predict Mortality in Intensive Care Unit: A Multicenter, Prospective, Cohort Study
OBSERVATIONAL
Inicio: 1 de ago de 2025
ID: NCT07068022
Completado
Fase 3
ClinicalTrials.gov
A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen
INTERVENTIONAL
Inicio: 1 de sept de 2003
ID: NCT00069745
Completado
Fase 4
ClinicalTrials.gov
A Multicenter, Single-arm, Open-label, Postmarketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
INTERVENTIONAL
Inicio: 25 de sept de 2013
ID: NCT01977651
Reclutando
Fase 3
ClinicalTrials.gov
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
INTERVENTIONAL
Inicio: 30 de sept de 2025
ID: NCT07106762
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
INTERVENTIONAL
Inicio: 1 de sept de 2010
ID: NCT01139762
Completado
Fase 3
ClinicalTrials.gov
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
INTERVENTIONAL
Inicio: 30 de nov de 2016
ID: NCT02928406
Completado
ClinicalTrials.gov
VeSpAR: A Randomized Controlled Trial Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Urethral Strictures
INTERVENTIONAL
Inicio: 26 de sept de 2018
ID: NCT03572348
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults
INTERVENTIONAL
Inicio: 1 de oct de 2012
ID: NCT01599806
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
INTERVENTIONAL
Inicio: 9 de oct de 2012
ID: NCT01668784
Reclutando
Fase 2
ClinicalTrials.gov
MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)
INTERVENTIONAL
Inicio: 3 de jul de 2025
ID: NCT06863272
Anterior
1
...
10
11
12
...
434
Siguiente
Filtros